Cardlytics Net Worth
Cardlytics Net Worth Breakdown | CDLX |
Cardlytics Net Worth Analysis
Cardlytics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Cardlytics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Cardlytics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Cardlytics' net worth analysis. One common approach is to calculate Cardlytics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Cardlytics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Cardlytics' net worth. This approach calculates the present value of Cardlytics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Cardlytics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Cardlytics' net worth. This involves comparing Cardlytics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Cardlytics' net worth relative to its peers.
Enterprise Value |
|
To determine if Cardlytics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Cardlytics' net worth research are outlined below:
| Cardlytics generated a negative expected return over the last 90 days | |
| Cardlytics has high historical volatility and very poor performance | |
| Cardlytics has high likelihood to experience some financial distress in the next 2 years | |
| Cardlytics currently holds 266.11 M in liabilities with Debt to Equity (D/E) ratio of 0.42, which is about average as compared to similar companies. Cardlytics has a current ratio of 0.88, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Cardlytics' use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 309.2 M. Net Loss for the year was (134.7 M) with profit before overhead, payroll, taxes, and interest of 127.65 M. | |
| Cardlytics currently holds about 157.04 M in cash with (185 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.77, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Cardlytics has a poor financial position based on the latest SEC disclosures | |
| Roughly 60.0% of Cardlytics shares are held by institutions such as insurance companies | |
| Latest headline from gurufocus.com: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Cardlytics, Inc. ... |
Cardlytics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Cardlytics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Cardlytics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 6th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Cardlytics Target Price Consensus
Cardlytics target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Cardlytics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 6 | Hold |
Most Cardlytics analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Cardlytics stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Cardlytics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationCardlytics Target Price Projection
Cardlytics' current and average target prices are 3.16 and 4.40, respectively. The current price of Cardlytics is the price at which Cardlytics is currently trading. On the other hand, Cardlytics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On Cardlytics Target Price
Know Cardlytics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Cardlytics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cardlytics backward and forwards among themselves. Cardlytics' institutional investor refers to the entity that pools money to purchase Cardlytics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | D. E. Shaw & Co Lp | 2024-09-30 | 573.3 K | Baillie Gifford & Co Limited. | 2024-09-30 | 567.4 K | General Equity Holdings Lp | 2024-09-30 | 533.5 K | Rbf Llc | 2024-09-30 | 488.1 K | Ubs O'connor Llc | 2024-09-30 | 450 K | Renaissance Technologies Corp | 2024-09-30 | 410.9 K | Pb Investment Partners, L.p. | 2024-09-30 | 397.1 K | Charles Schwab Investment Management Inc | 2024-09-30 | 390.3 K | Gsa Capital Partners Llp | 2024-09-30 | 382.3 K | Blackrock Inc | 2024-09-30 | 3.1 M | Vanguard Group Inc | 2024-09-30 | 2.7 M |
Follow Cardlytics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 160.6 M.Market Cap |
|
Project Cardlytics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.65) | (0.69) | |
| Return On Capital Employed | (0.30) | (0.32) | |
| Return On Assets | (0.21) | (0.22) | |
| Return On Equity | (1.15) | (1.09) |
When accessing Cardlytics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Cardlytics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Cardlytics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Cardlytics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Cardlytics. Check Cardlytics' Beneish M Score to see the likelihood of Cardlytics' management manipulating its earnings.
Evaluate Cardlytics' management efficiency
Cardlytics has return on total asset (ROA) of (0.0762) % which means that it has lost $0.0762 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8612) %, meaning that it created substantial loss on money invested by shareholders. Cardlytics' management efficiency ratios could be used to measure how well Cardlytics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.69 in 2025. Return On Capital Employed is likely to drop to -0.32 in 2025. At this time, Cardlytics' Net Tangible Assets are fairly stable compared to the past year. Intangibles To Total Assets is likely to rise to 0.55 in 2025, whereas Total Assets are likely to drop slightly above 440 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.32 | 3.49 | |
| Tangible Book Value Per Share | (4.98) | (5.23) | |
| Enterprise Value Over EBITDA | (5.93) | (6.22) | |
| Price Book Value Ratio | 2.24 | 3.76 | |
| Enterprise Value Multiple | (5.93) | (6.22) | |
| Price Fair Value | 2.24 | 3.76 | |
| Enterprise Value | 586.9 M | 557.5 M |
The decision-making processes within Cardlytics are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Enterprise Value Revenue 1.0752 | Revenue | Quarterly Revenue Growth (0.15) | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cardlytics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cardlytics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cardlytics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cardlytics Corporate Filings
F4 | 6th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 3rd of January 2025 Other Reports | ViewVerify | |
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 6th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Cardlytics Earnings Estimation Breakdown
The calculation of Cardlytics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Cardlytics is estimated to be -0.1585 with the future projection ranging from a low of -0.205 to a high of -0.125. Please be aware that this consensus of annual earnings estimates for Cardlytics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.2 Lowest | Expected EPS | -0.12 Highest |
Cardlytics Earnings Projection Consensus
Suppose the current estimates of Cardlytics' value are higher than the current market price of the Cardlytics stock. In this case, investors may conclude that Cardlytics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Cardlytics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2024 | Current EPS (TTM) | |
| 6 | 31.48% | -0.15 | -0.1585 | -6.4 |
Cardlytics Earnings per Share Projection vs Actual
Actual Earning per Share of Cardlytics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Cardlytics predict the company's earnings will be in the future. The higher the earnings per share of Cardlytics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Cardlytics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Cardlytics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Cardlytics should always be considered in relation to other companies to make a more educated investment decision.Cardlytics Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Cardlytics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-06 | 2024-09-30 | -0.24 | -0.15 | 0.09 | 37 | ||
2024-08-07 | 2024-06-30 | -0.13 | -0.15 | -0.02 | 15 | ||
2024-05-08 | 2024-03-31 | -0.11 | -0.09 | 0.02 | 18 | ||
2024-03-14 | 2023-12-31 | 0.12 | 0.14 | 0.02 | 16 | ||
2023-11-08 | 2023-09-30 | -0.01 | 0.01 | 0.02 | 200 | ||
2023-08-01 | 2023-06-30 | -0.35 | -0.24 | 0.11 | 31 | ||
2023-05-04 | 2023-03-31 | -0.56 | -0.25 | 0.31 | 55 | ||
2023-03-01 | 2022-12-31 | -0.46 | -0.29 | 0.17 | 36 | ||
2022-11-01 | 2022-09-30 | -0.57 | -0.5 | 0.07 | 12 | ||
2022-08-02 | 2022-06-30 | -0.47 | -0.65 | -0.18 | 38 | ||
2022-05-02 | 2022-03-31 | -0.55 | -0.38 | 0.17 | 30 | ||
2022-03-01 | 2021-12-31 | -0.42 | -0.15 | 0.27 | 64 | ||
2021-11-02 | 2021-09-30 | -0.54 | -0.33 | 0.21 | 38 | ||
2021-08-03 | 2021-06-30 | -0.39 | -0.39 | 0.0 | 0 | ||
2021-05-04 | 2021-03-31 | -0.34 | -0.34 | 0.0 | 0 | ||
2021-03-01 | 2020-12-31 | -0.03 | -0.05 | -0.02 | 66 | ||
2020-11-02 | 2020-09-30 | -0.28 | -0.16 | 0.12 | 42 | ||
2020-08-04 | 2020-06-30 | -0.47 | -0.38 | 0.09 | 19 | ||
2020-05-11 | 2020-03-31 | -0.21 | -0.26 | -0.05 | 23 | ||
2020-03-03 | 2019-12-31 | 0.04 | 0.18 | 0.14 | 350 | ||
2019-11-12 | 2019-09-30 | -0.15 | 0.03 | 0.18 | 120 | ||
2019-08-08 | 2019-06-30 | -0.22 | -0.12 | 0.1 | 45 | ||
2019-05-09 | 2019-03-31 | -0.36 | -0.23 | 0.13 | 36 | ||
2019-03-05 | 2018-12-31 | -0.17 | -0.06 | 0.11 | 64 | ||
2018-11-13 | 2018-09-30 | -0.5 | -0.15 | 0.35 | 70 | ||
2018-08-14 | 2018-06-30 | -0.52 | -0.59 | -0.07 | 13 | ||
2018-05-10 | 2018-03-31 | -0.62 | -1.54 | -0.92 | 148 | ||
2018-03-19 | 2017-12-31 | -0.56 | -0.18 | 0.38 | 67 | ||
2017-11-29 | 2017-09-30 | 0 | -0.3 | -0.3 | 0 | ||
2017-09-21 | 2017-06-30 | 0 | -0.28 | -0.28 | 0 | ||
2017-06-16 | 2017-03-31 | 0 | -0.65 | -0.65 | 0 |
Cardlytics Corporate Management
| Evelyne Forester | Chief Officer | Profile | |
| Carson Napps | Chief Officer | Profile | |
| Jose Singer | Chief Officer | Profile | |
| Alexis DeSieno | Chief Officer | Profile | |
| Karim Temsamani | CEO Director | Profile | |
| James Hart | VP People | Profile |
Additional Tools for Cardlytics Stock Analysis
When running Cardlytics' price analysis, check to measure Cardlytics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cardlytics is operating at the current time. Most of Cardlytics' value examination focuses on studying past and present price action to predict the probability of Cardlytics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cardlytics' price. Additionally, you may evaluate how the addition of Cardlytics to your portfolios can decrease your overall portfolio volatility.